Is X-linked methyl-CpG binding protein 2 a new target for the treatment of Parkinson's disease?***

    loading  Checking for direct PDF access through Ovid

Abstract

Research Highlights

(1) X-linked methyl-CpG binding protein 2 and tyrosine hydroxylase expression is reduced in 6-hydroxydopamine-treated cells.

Research Highlights

(2) Overexpression of X-linked methyl-CpG binding protein 2 in SH-SY5Y cells reduced cell apoptosis induced by 6-hydroxydopamine and increased tyrosine hydroxylase expression.

Research Highlights

(3) X-linked methyl-CpG binding protein 2 inhibited 6-hydroxydopamine-induced apoptosis by increasing tyrosine hydroxylase expression in SH-SY5Y cells.

Research Highlights

(4) X-linked methyl-CpG binding protein 2 may be a potential therapeutic target for Parkinson's disease.

X-linked methyl-CpG binding protein 2 mutations can induce symptoms similar to those of Parkinson's disease and dopamine metabolism disorders, but the specific role of X-linked methyl-CpG binding protein 2 in the pathogenesis of Parkinson's disease remains unknown. In the present study, we used 6-hydroxydopamine-induced human neuroblastoma cell (SH-SY5Y cells) injury as a cell model of Parkinson's disease. The 6-hydroxydopamine (50 μmol/L) treatment decreased protein levels for both X-linked methyl-CpG binding protein 2 and tyrosine hydroxylase in these cells, and led to cell death. However, overexpression of X-linked methyl-CpG binding protein 2 was able to ameliorate the effects of 6-hydroxydopamine, it reduced 6-hydroxydopamine-induced apoptosis, and increased the levels of tyrosine hydroxylase in SH-SY5Y cells. These findings suggesting that X-linked methyl-CpG binding protein 2 may be a potential therapeutic target for the treatment of Parkinson's disease.

Related Topics

    loading  Loading Related Articles